- Home
- USAU vs IKT Comparison
USAU vs IKT Comparison
Compare USAU & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAU
- IKT
- Stock Information
- Founded
- USAU 2014
- IKT 2008
- Country
- USAU United States
- IKT United States
- Employees
- USAU N/A
- IKT N/A
- Industry
- USAU Precious Metals
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- USAU Basic Materials
- IKT Health Care
- Exchange
- USAU Nasdaq
- IKT Nasdaq
- Market Cap
- USAU 126.8M
- IKT 140.5M
- IPO Year
- USAU N/A
- IKT 2020
- Fundamental
- Price
- USAU $11.34
- IKT $1.75
- Analyst Decision
- USAU Strong Buy
- IKT Buy
- Analyst Count
- USAU 2
- IKT 2
- Target Price
- USAU $17.00
- IKT $8.00
- AVG Volume (30 Days)
- USAU 237.1K
- IKT 115.2K
- Earning Date
- USAU 09-15-2025
- IKT 08-14-2025
- Dividend Yield
- USAU N/A
- IKT N/A
- EPS Growth
- USAU N/A
- IKT N/A
- EPS
- USAU N/A
- IKT N/A
- Revenue
- USAU N/A
- IKT N/A
- Revenue This Year
- USAU N/A
- IKT N/A
- Revenue Next Year
- USAU N/A
- IKT N/A
- P/E Ratio
- USAU N/A
- IKT N/A
- Revenue Growth
- USAU N/A
- IKT N/A
- 52 Week Low
- USAU $4.86
- IKT $1.12
- 52 Week High
- USAU $14.39
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- USAU 46.34
- IKT 50.99
- Support Level
- USAU $11.80
- IKT $1.61
- Resistance Level
- USAU $12.66
- IKT $1.88
- Average True Range (ATR)
- USAU 0.55
- IKT 0.16
- MACD
- USAU 0.08
- IKT 0.02
- Stochastic Oscillator
- USAU 48.64
- IKT 72.04
About USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.